Posterior segment injury developed after injection of anesthetics on eyelids with needleless jet injection device

J. E. Lee,H. Choi,Jong Soo Lee,B. Oum

DOI: https://doi.org/10.1007/s00417-006-0309-3

2006-04-22

Abstract:

What problem does this paper attempt to address?

Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting

Lei Lv,Brenna L Brady,Lin Xie,Mico Guevarra,Alexander Turchin

DOI: https://doi.org/10.1016/j.pcd.2024.06.013

Abstract:Aims: To investigate real-world treatment adherence and persistence in people with type 2 diabetes newly initiating oral semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), or a dipeptidyl peptidase-4 inhibitor (DPP-4i). Methods: This retrospective cohort study used the Merative™ MarketScan® Commercial and Medicare databases. Index date was the first fill for the cohort medication. Adherence was defined as proportion of days covered (PDC) over the 12-month post-index period ('adherent' = ≥0.8). Persistence was number of days until discontinuation, based on a 45-day gap. Results were compared between cohorts using inverse probability treatment weighting. Results: Oral semaglutide (n=5485) and DPP-4i (n=4980) cohorts had similar percentages of people who were adherent (PDC ≥0.8; 41.6 % vs. 42.9 %; P = 0.182) and persistent for ≥9 months (45.0 % vs. 46.3 %; P = 0.185). The DPP-4i cohort used significantly more anti-diabetic medication (ADM) classes over the post-index period (mean±SD: 2.6±1.0 vs. 2.9±1.1, P < 0.001), with 23.2 % filling a GLP-1 RA in the post-period. Conclusions: Adherence and persistence were similar between cohorts. However, there are potential benefits to prescribing oral semaglutide over DPP-4is, including reduced need for additional ADM.
Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings

Hodaka Yamada,Masashi Yoshida,Shunsuke Funazaki,Jun Morimoto,Shiori Tonezawa,Asuka Takahashi,Shuichi Nagashima,Kimura Masahiko,Otsuka Kiyoshi,Kazuo Hara

DOI: https://doi.org/10.3390/jcdd10040176

2023-04-18

Abstract:Glucagon-like peptide-1 receptor agonists (GLP-1RA) have a more potent glycated hemoglobin (HbA1c)-lowering effect than existing therapies and are widely used for treating type 2 diabetes mellitus (T2DM). Once-daily oral semaglutide is the world's first oral GLP-1RA. This study aimed to provide real-world data on oral semaglutide in Japanese patients with T2DM and its effects on cardiometabolic parameters. This was a single-center retrospective observational study. We examined changes in HbA1c and body weight (BW) and the rate of achieving HbA1c < 7% after 6 months of oral semaglutide treatment in Japanese patients with T2DM. Furthermore, we examined differences in the efficacy of oral semaglutide with multiple patient backgrounds. A total of 88 patients were included in this study. Overall, the mean (standard error of the mean) HbA1c at 6 months decreased by -1.24% (0.20%) from baseline, and BW at 6 months (n = 85) also decreased by -1.44 kg (0.26 kg) from baseline. The percentage of patients who achieved HbA1c < 7% changed significantly from 14% at baseline to 48%. HbA1c decreased from baseline regardless of age, sex, body mass index, chronic kidney disease, or diabetes duration. Additionally, alanine aminotransferase, total cholesterol, triglyceride, and non-high-density lipoprotein cholesterol were significantly reduced from baseline. Oral semaglutide may be an effective option for the intensification of therapy in Japanese patients with T2DM who have inadequate glycemic control with existing therapy. It may also reduce BW and improve cardiometabolic parameters.
A meta-analysis of thoracic radiotherapy for small-cell lung cancer.

J. Pignon,R. Arriagada,D. Ihde,David H. Johnson,M. Perry,R. Souhami,O. Brodin,R. Joss,M. Kies,B. Lebeau,T. Onoshi,K. Østerlind,M. Tattersall,H. Wagner

DOI: https://doi.org/10.1056/NEJM199212033272302

IF: 158.5

1992-12-03

New England Journal of Medicine

Abstract:BACKGROUND In spite of 16 randomized trials conducted during the past 15 years, the effect of thoracic radiotherapy on the survival of patients with limited small-cell lung cancer remains controversial. The majority of these trials did not have enough statistical power to detect a difference in survival of 5 to 10 percent at five years. This meta-analysis was designed to evaluate the hypothesis that thoracic radiotherapy contributes to a moderate increase in overall survival in limited small-cell lung cancer. METHODS We collected individual data on all patients enrolled before December 1988 in randomized trials comparing chemotherapy alone with chemotherapy combined with thoracic radiotherapy. Trials that included only patients with extensive disease were excluded. RESULTS The meta-analysis included 13 trials and 2140 patients with limited disease. A total of 433 patients with extensive disease were excluded. Overall, 1862 of 2103 patients who could be evaluated died; the median follow-up period for the surviving patients was 43 months. The relative risk of death in the combined-therapy group as compared with the chemotherapy group was 0.86 (95 percent confidence interval, 0.78 to 0.94; P = 0.001), corresponding to a 14 percent reduction in the mortality rate. The benefit in terms of overall survival at three years (+/- SD) was 5.4 +/- 1.4 percent. Indirect comparison of early with late radiotherapy and of sequential with non-sequential radiotherapy did not reveal any optimal time for treatment. There was a trend toward a larger reduction in mortality among younger patients: the relative risk of death in the combined-therapy as compared with the chemotherapy group ranged from 0.72 for patients less than 55 years old (95 percent confidence interval, 0.56 to 0.93) to 1.07 (0.70 to 1.64) for patients over 70. CONCLUSIONS Thoracic radiotherapy moderately improves survival in patients with limited small-cell lung cancer who are treated with combination chemotherapy. Identification of the optimal combination of chemotherapy and radiotherapy will require further trials.
In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis.

P. M. Pinto,Rita de Cássia Botelho Weikert-Oliveira,J. Lyon,V. F. Cury,R. Arantes,C. Koga‐Ito,M. A. Resende

DOI: https://doi.org/10.1016/J.MICRES.2006.08.007

2008-09-01

Microbiology Research

Abstract:
Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data

Hisayuki Katsuyama,Mariko Hakoshima,Emika Kaji,Masaaki Mino,Eiji Kakazu,Sakura Iida,Hiroki Adachi,Tatsuya Kanto,Hidekatsu Yanai

DOI: https://doi.org/10.3390/biomedicines12051001

IF: 4.757

2024-05-03

Biomedicines

Abstract:Once-weekly semaglutide is a widely used glucagon-like peptide-1 receptor agonist (GLP-1RA) used for the treatment of type 2 diabetes (T2D). In clinical trials, semaglutide improved glycemic control and obesity, and reduced major cardiovascular events. However, the reports are limited on its real-world efficacy relating to various metabolic factors such as dyslipidemia or metabolic dysfunction-associated steatotic liver disease (MASLD) in Asian patients with T2D. In our retrospective longitudinal study, we selected patients with T2D who were given once-weekly semaglutide and compared metabolic parameters before and after the start of semaglutide. Seventy-five patients were eligible. HbA1c decreased significantly, by 0.7–0.9%, and body weight by 1.4–1.7 kg during the semaglutide treatment. Non-HDL cholesterol decreased significantly at 3, 6 and 12 months after the initiation of semaglutide; LDL cholesterol decreased at 3 and 6 months; and HDL cholesterol increased at 12 months. The effects on body weight, HbA1c and lipid profile were pronounced in patients who were given semaglutide as a first GLP-1RA (GLP-1R naïve), whereas improvements in HbA1c were also observed in patients who were given semaglutide after being switched from other GLP-1RAs. During a 12-month semaglutide treatment, the hepatic steatosis index (HSI) tended to decrease. Moreover, a significant decrease in the AST-to-platelet ratio index (APRI) was observed in GLP-1RA naïve patients. Our real-world study confirmed the beneficial effects of once-weekly semaglutide, namely, improved body weight, glycemic control and atherogenic lipid profile. The beneficial effects on MASLD were also suggested.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial

John B Buse,Helene Nordahl Christensen,Brian J Harty,Julie Mitchell,Benjamin P Soule,Emily Zacherle,Mark Cziraky,Vincent J Willey

DOI: https://doi.org/10.1136/bmjdrc-2022-003206

Abstract:Introduction: Once-weekly subcutaneous semaglutide, a glucagon-like peptide-1 analog, is approved in the USA as an adjunct to diet and exercise for adults with inadequately controlled type 2 diabetes (T2D) to improve glycemic control and reduce the risk of major adverse cardiovascular events in people with T2D and established cardiovascular disease. The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) phase III clinical trial program demonstrated the efficacy and safety of once-weekly subcutaneous semaglutide; however, determining its effectiveness in a real-world setting could support decision-making by clinicians, payers and policy makers in routine clinical practice. Research design and methods: SEmaglutide PRAgmatic (SEPRA) is an ongoing open-label, randomized, pragmatic clinical trial designed to compare the effects of once-weekly subcutaneous semaglutide versus standard of care in US health-insured adults with T2D and physician-determined inadequate glycemic control. The primary end point is the proportion of participants achieving glycated hemoglobin (HbA1c) <7.0% at year 1; other key outcomes include glycemic control, weight loss, healthcare utilization, and patient-reported outcomes. Individual-level data will be collected from routine clinical practice and health insurance claims. The last patient last visit is expected by June 2023. Results: Between July 2018 and March 2021, 1278 participants were enrolled from 138 study sites across the USA. At baseline, 54% were male with mean±SD age 57.4±11.1 years and body mass index 35.7±8.0 kg/m2. Mean diabetes duration was 7.4±6.0 years and mean HbA1c was 8.5±1.6%. At baseline, concomitant antidiabetes medications included metformin, sulfonylureas, sodium-glucose co-transporter-2 inhibitors, and dipeptidyl peptidase-4 inhibitors. The majority of participants had hypertension and dyslipidemia. The trial design was self-assessed using the PRagmatic Explanatory Continuum Indicator Summary-2 tool by the study steering group and was scored 4-5 in all domains suggesting a highly pragmatic study. Conclusions: SEPRA, a highly pragmatic ongoing study, will provide data on the effects of once-weekly subcutaneous semaglutide in a real-world setting when used during routine management of T2D. Trial registration number: NCT03596450.
Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice

Reema Mody,Janna Manjelievskaia,Elizabeth H Marchlewicz,Raleigh E Malik,Nicole M Zimmerman,Debra E Irwin,Maria Yu

DOI: https://doi.org/10.1016/j.clinthera.2022.01.017

Abstract:Purpose: Greater medication adherence and persistence have been associated with improved glycemic control in patients with type 2 diabetes mellitus. This study compared adherence, persistence, and treatment patterns among patients naïve to glucagon-like peptide 1 receptor agonists initiating once-weekly injectable treatment with dulaglutide versus semaglutide over 6-month (6M) and 12-month (12M) follow-up periods. Methods: This retrospective, observational cohort study used administrative claims data from three IBM MarketScan research databases. Data from adult patients with type 2 diabetes newly initiating treatment with dulaglutide or semaglutide between January 2018 and January 2020 (index date was defined as the earliest fill date), without evidence of glucagon-like peptide 1 receptor agonist use in the 6M baseline period, and with continuous enrollment in the 6M baseline and 6M or 12M follow-up period were included. Dulaglutide initiators were propensity score-matched, in a 1:1 ratio, to semaglutide initiators in each 6M and 12M follow-up cohort (26,284 and 13,837 pairs, respectively). Findings: In the matched cohorts, baseline characteristics were balanced; the mean age was 53 years, and 50% of patients were women. Compared to semaglutide initiators, dulaglutide initiators were more adherent (6M, 63.4% vs 47.8%; 12M, 54.4% vs 43.3%; both, P < 0.0001), more persistent on therapy (6M, 72% vs 62%, 12M, 55.5% vs 45.3%, both, P < 0.001), and had more mean days of persistence (6M, 145 vs 132, 12M, 254.3 vs 220.7; both, P < 0.001). Implications: At both 6M and 12M follow-up, dulaglutide initiators had significantly greater adherence and greater persistence compared with matched semaglutide initiators.
Ultrafast laser ablation giving unstructured surface roughness prior to the emergence of LIPSS

M. Ardron,D. Hand

DOI: https://doi.org/10.1109/CLEOE-IQEC.2013.6801580

2013-05-12

Abstract:Since the first published observations of laser induced period surface structures (LIPSS) [1], such features have been produced by many research groups but aspects of the mechanism behind the emergence of these features remain unclear. Surface plasmons provide a periodic field which is understood to be involved in the formation of LIPSS as described in various publications [2-7]. However, when the incident laser energy is normal to the target surface LIPSS are formed despite there being no incoming vector component along the target surface, and hence no periodic energy structure to excite surface plasmons. A reasonable explanation is that if the surface is sufficiently rough, it will scatter the light and thereby provide periodic energy components parallel to the target surface. In this case spatial frequency components of the surface roughness could act as gratings to satisfy k vector matching to the plasmons [8]. LIPSS formation would therefore be expected to be strongly dependent on the initial surface roughness.
Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study)

Irene Caballero Mateos,María Dolores García de Lucas,Viyey Kishore Doulatram-Gamgaram,Paloma Moreno-Moreno,Ana Isabel Jimenez-Millan,Manuel Botana-López,Juan Francisco Merino-Torres,Alfonso Soto-Gónzalez,José Carlos Fernández-García,Cristóbal Morales-Portillo

DOI: https://doi.org/10.3390/nu16152545

IF: 5.9

2024-08-03

Nutrients

Abstract:Although, in randomized clinical trials, once-weekly subcutaneous semaglutide (OW s.c.) has demonstrated superior efficacy in comparison with placebo and active controls in terms of glycemic control and body weight reduction in patients with type 2 diabetes mellitus (T2DM), these results need to be confirmed in a real-world (RW) setting. An RW ambispective study (6 months retrospective and 6 months prospective) was conducted in 10 tertiary hospitals in Spain. We evaluated changes in HbA1c and body weight in patients with T2DM treated with semaglutide OW s.c. Additionally, we analyzed different subgroups of patients treated with semaglutide OW s.c. as an add-on to glucose-lowering therapy. A total of 752 patients with a mean age of 60.2 years, a mean HbA1c level of 8.5%, a mean body weight of 101.6 kg, and a mean T2DM duration of 10 years were included. At 12 months, compared with baseline, there was a mean difference of -2.1% in HbA1c levels (p < 0.001) and a mean difference of 9.2 kg in body weight (p < 0.001). Moreover, there were statistically significant differences (p < 0.001) between baseline and month 12 in both HbA1c and body weight in the four subgroups receiving semaglutide OW s.c. as an add-on to glucose-lowering therapy. Semaglutide OW s.c. was well tolerated, with gastrointestinal disorders being the most commonly reported side effects. In this RW study, 12 months of treatment with semaglutide OW s.c. in patients with T2DM was associated with significant and clinically relevant improvements in glycemic control and weight loss, regardless of the glucose-lowering therapy received, and the overall safety profile was positive.
PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice

Daisuke Yabe,Yoshiyuki Hamamoto,Daiji Kawanami,Rimei Nishimura,Yasuo Terauchi,Hanan Amadid,Uffe Christian Braae,Atheline Major‐Pedersen,Ryo Suzuki

DOI: https://doi.org/10.1111/jdi.14291

2024-08-25

Journal of Diabetes Investigation

Abstract:PIONEER REAL Japan was a non‐interventional study in which oral semaglutide was investigated in participants with type 2 diabetes in routine clinical practice. Study participants had significant reductions in glycated hemoglobin and bodyweight after oral semaglutide initiation, including among participants aged ≥75 years, with no new safety findings identified. This study provides insights into oral semaglutide use in a diverse real‐world population of Japanese adults with type 2 diabetes. Aims/Introduction PIONEER REAL Japan was a non‐interventional prospective study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. Materials and Methods Adults naïve to injectable glucose‐lowering therapies initiated oral semaglutide in routine clinical practice and were followed for 34–44 weeks. The primary endpoint was change in glycated hemoglobin (HbA1c) from baseline to end of study; the co‐primary endpoint was number of adverse events (AEs). Secondary endpoints included change in bodyweight from baseline to end of study. Analyses were also carried out for subgroups aged <75 and ≥75 years. Results A total of 624 participants initiated oral semaglutide; 578 completed the study. Mean baseline HbA1c and bodyweight were 7.7% and 72.4 kg, respectively. At end of study, estimated change (95% confidence interval [CI]) in HbA1c from baseline was −0.7 percentage points (−0.77, −0.61) overall, −0.8 percentage points (−0.86, −0.67) in the <75 years subgroup and −0.5 percentage points (−0.68, −0.41) in the ≥75 years subgroup (all P

endocrinology & metabolism
Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study

B. M. Bonora,G. Russo,F. Leonetti,M. Strazzabosco,L. Nollino,G. Aimaretti,A. Giaccari,F. Broglio,A. Consoli,A. Avogaro,G. P. Fadini,

DOI: https://doi.org/10.1007/s40618-024-02309-2

2024-02-18

Journal of Endocrinological Investigation

Abstract:Abstract Aim Oral semaglutide, an innovative orally administered GLP-1 receptor agonist for type 2 diabetes (T2D) management was herein evaluated for its effectiveness in a multi-center retrospective real-world study. Methods We included new-users of oral semaglutide from 18 specialist care centres and collected retrospective data on baseline clinical characteristics. Updated values of HbA1c and body weight were analyzed using the mixed model for repeated measures. Results The study included 166 individuals with T2D, predominantly men (64.5%), with a mean age of 64.4 years and a mean diabetes duration of 10.1 years. In the majority of patients (68.3%) oral semaglutide was used as a second-line drug, mostly with metformin. At baseline, mean BMI was 28.9 kg/m 2 and HbA1c was 7.5%. During the 18-month observation period, oral semaglutide demonstrated significant reductions in HbA1c, with a maximum change of − 0.9%, and 42.1% of patients achieved HbA1c values below 7.0%. Additionally, there was a substantial reduction in body weight, with an estimated change of − 3.4 kg at 18 months, and 30.3% of patients experienced a 5% or greater reduction in baseline body weight. Only 24.2% of patients reached the 14 mg dose. Subgroup analysis revealed that baseline HbA1c > 7%, persistence on drug, not being on a prior therapy with DPP-4 inhibitors, and loosing 5% or more the initial body weight were associated with greater HbA1c reductions. Conclusion This study supports oral semaglutide as an effective option for T2D treatment, offering improved glucose control and weight management in a real-world setting.

endocrinology & metabolism
PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan

Ryo Suzuki,Hanan Amadid,Atheline Major‐Pedersen,Daisuke Yabe

DOI: https://doi.org/10.1111/jdi.14219

2024-05-07

Journal of Diabetes Investigation

Abstract:PIONEER REAL Japan was a non‐interventional single‐arm study investigating the oral glucagon‐like peptide‐1 (GLP‐1) analog semaglutide in routine clinical practice. This article describes the characteristics of 624 individuals with type 2 diabetes prescribed oral semaglutide, and thereby provides insights into Japanese individuals prescribed oral semaglutide in clinical practice. Aims/Introduction PIONEER REAL Japan was a non‐interventional, multicenter, prospective study investigating oral semaglutide in adults with type 2 diabetes in routine clinical practice. We report baseline characteristics of participants enrolled in this study. Materials and Methods Adults aged ≥20 years with type 2 diabetes but no previous treatment with injectable glucose‐lowering medication were enrolled. Participants initiated oral semaglutide at their treating physician's discretion and were followed for 34–44 weeks. Participants were stratified into <75‐year‐old and ≥75‐year‐old subgroups. Results A total of 624 participants initiated the study. The mean (standard deviation) age was 64.1 years (14.1), the mean (standard deviation) body weight was 72.4 kg (16.1), and the mean (standard deviation) body mass index was 27.5 kg/m2 (5.0). Participants had a median (interquartile range) type 2 diabetes duration of 9.3 years (4.2, 15.2) and mean (standard deviation) glycated hemoglobin 7.7% (1.1). Most (75.6%) participants were taking glucose‐lowering medications at baseline; the most common was metformin (51.9%). The main reasons for initiating oral semaglutide were glycemic control and weight loss. Most (86.0%) participants had an individualized target for glycemic control of glycated hemoglobin ≤7%. The <75‐year‐old subgroup was heavier (mean [standard deviation] body mass index 28.6 kg/m2 [5.2] vs 25.1 kg/m2 [3.4]) but had comparable glycated hemoglobin levels (mean [standard deviation] 7.7% [1.2] vs 7.8% [1.0]) to the ≥75‐year‐old subgroup. Conclusions PIONEER REAL Japan describes the characteristics of individuals with type 2 diabetes prescribed oral semaglutide. The baseline characteristics provide insights into Japanese individuals with type 2 diabetes prescribed oral semaglutide in clinical practice.

endocrinology & metabolism
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study)

Sho Furusawa,Hiroshi Nomoto,Hiroki Yokoyama,Yuka Suzuki,Atsushi Tsuzuki,Kiyohiko Takahashi,Aika Miya,Hiraku Kameda,Kyu Yong Cho,Jun Takeuchi,So Nagai,Shinji Taneda,Yoshio Kurihara,Akinobu Nakamura,Tatsuya Atsumi,SWITCH-SEMA 2 study group

DOI: https://doi.org/10.1111/dom.15393

Abstract:Aim: To assess whether oral semaglutide provides better glycaemic control, compared with dipeptidyl peptidase-4 inhibitor (DPP-4i) continuation, in people with type 2 diabetes. Materials and methods: In this multicentre, open-label, prospective, randomized, parallel-group comparison study, participants receiving DPP-4is were either switched to oral semaglutide (3-14 mg/day) or continued on DPP-4is. The primary endpoint was the change in glycated haemoglobin (HbA1c) over 24 weeks. Secondary endpoints included changes in metabolic parameters and biomarkers, along with the occurrence of adverse events. Factors associated with HbA1c improvement were also explored. Results: In total, 174 eligible participants were enrolled; 17 dropped out of the study. Consequently, 82 participants in the DPP-4i group and 75 participants in the semaglutide group completed the study and were included in the analysis. Improvement in HbA1c at week 24 was significantly greater when switching to semaglutide compared with DPP-4i continuation [-0.65 (95% confidence interval: -0.79, -0.51) vs. +0.05 (95% confidence interval: -0.07, 0.16) (p < .001)]. Body weight, lipid profiles and liver enzymes were significantly improved in the semaglutide group than in the DPP-4i continuation group. Multiple linear regression analysis revealed that baseline HbA1c and homeostasis model assessment 2-R were independently associated with HbA1c improvement after switching to semaglutide. Seven participants in the semaglutide group discontinued medication because of gastrointestinal symptoms. Conclusions: Although the potential for gastrointestinal symptoms should be carefully considered, switching from DPP-4is to oral semaglutide may be beneficial for glycaemic control and metabolic abnormalities in people with higher HbA1c and insulin resistance.
Once‐weekly semaglutide use in patients with type 2 diabetes: real‐world data from the SURE Italy observational study

Raffaele Napoli,Cesare Berra,Andrei‐Mircea Catarig,Chiara Di Loreto,Emily Donatiello,Tina Landsvig Berentzen,Dario Pitocco,Francesco Giorgino

DOI: https://doi.org/10.1111/dom.15020

2023-02-16

Diabetes, Obesity and Metabolism

Abstract:Aims SURE Italy, a multicentre, prospective, open‐label, observational, real‐world study, investigated once‐weekly (OW) semaglutide in patients with type 2 diabetes (T2D) in routine clinical practice. Materials and methods Adults with T2D and ≥1 documented HbA1c level within 12 weeks of semaglutide initiation were enrolled. The primary endpoint was change in HbA1c from baseline to end of study (EOS; ~30 weeks). Other endpoints included changes in body weight (BW), waist circumference and patient‐reported outcomes (PROs), and the proportion of patients achieving HbA1c <7.0% or <6.5%, weight loss ≥5% and a post‐hoc composite endpoint (HbA1c reduction of ≥1%‐point and weight loss ≥5%). These endpoints were reported for patients on semaglutide at EOS (effectiveness analysis set [EAS]). Safety data were reported in the full analysis set (FAS). Results Of 579 patients who initiated semaglutide (FAS), 491 completed the study on treatment (EAS). Mean baseline HbA1c was 8.0%, and 20.7% (120/579) of patients had HbA1c <7.0%. Mean semaglutide dose at EOS was 0.66 ± 0.28 mg. In the EAS, mean HbA1c and BW decreased by 1.1%‐point (95% confidence interval [CI] 1.20,1.05; p<0.0001) and 4.2 kg (95% CI 4.63,3.67; p<0.0001), respectively. At EOS, 61.7% and 40.8% of patients achieved HbA1c <7.0% and <6.5%, respectively, 40.5% achieved weight loss ≥5% and 25.3% achieved the post‐hoc composite endpoint. PROs improved from baseline to EOS. No new safety concerns were identified. Conclusions In routine clinical practice in Italy, patients with T2D treated with OW semaglutide for 30 weeks achieved clinically significant improvements in HbA1c, BW and other outcomes. This article is protected by copyright. All rights reserved.

endocrinology & metabolism
Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics

Tetsuaki Inokuchi,Yoshihide Fukumoto,Gendai Lee,Yoshifumi Yokomizo,Kokichi Tanaka,Michiko Chosa,Masaru Doi,Noboru Tamaki,Seiichi Goto,Kojiro Ichikawa,Kazuo Kobayashi

DOI: https://doi.org/10.1111/jdi.14225

2024-05-05

Journal of Diabetes Investigation

Abstract:Oral semaglutide treatment is effective and well tolerated for managing type 2 diabetes mellitus over a relatively long periods in clinical practice in Japan. Patients with obesity may experience significant improvements in metabolic factors induced by oral semaglutide treatment. This new oral GLP1Ra can contribute sufficiently to the strategy of treating patients with type 2 diabetes mellitus who require BW management. Introduction Glucagon‐like peptide 1 receptor agonists (GLP1Ras) have emerged as pivotal agents in diabetes management and organ protection. However, their use is limited due to the necessity for injectable administration. The advent of the first oral GLP1Ra (oral semaglutide) in Japan since 2021 is expected to expand its usage. The aim of this study is to survey the efficacy and tolerability of oral semaglutide in clinical practice. Materials and Methods We retrospectively analyzed 120 outpatients diagnosed with type 2 diabetes mellitus who had received oral semaglutide for >6 months. Changes in clinical parameters during oral semaglutide treatment from baseline to 12 months were analyzed. The inverse probability weighting method using the propensity score was used to evaluate the differences in clinical parameters at 6 months after treatment, based on the patients' obesity levels. Results Body weight (BW), glycated hemoglobin A1c (HbA1c), and alanine aminotransferase (ALT) levels at baseline decreased significantly after treatment compared with those at 12 months (P

endocrinology & metabolism
Doppler tissue imaging in the assessment of atrioventricular conduction time: validation of a novel technique and comparison with electrophysiologic and pulsed wave Doppler-derived equivalents in an animal model.

M. Nii,M. Shimizu,K. Roman,I. Konstantinov,Jia Li,A. Redington,E. Jaeggi

DOI: https://doi.org/10.1016/J.ECHO.2005.09.010

IF: 7.722

2006-03-01

Journal of the American Society of Echocardiography

Abstract:
Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts

Gian Paolo Fadini,Benedetta Maria Bonora,Mariangela Ghiani,Roberto Anichini,Elena Melchionda,Bruno Fattor,Stefano Fazion,Giancarla Meregalli,Andrea Giaccari,Angelo Avogaro,Agostino Consoli,the GLIMPLES study investigators

DOI: https://doi.org/10.1111/dom.15554

2024-03-15

Diabetes Obesity and Metabolism

Abstract:Aim To investigate the real‐world utilization and comparative clinical outcomes of injectable and oral semaglutide in individuals with type 2 diabetes (T2D) with the aim of enhancing understanding of the practical implications associated with choosing between these formulations. Methods New users of oral or injectable semaglutide were selected from a cohort of 14 079 initiators of glucagon‐like peptide‐1 receptor agonists. Propensity‐score matching (PSM) was employed to create balanced groups, ensuring comparability. The analysis encompassed dose exposure, drug persistence, and clinical outcomes, including changes in glycated haemoglobin (HbA1c) and body weight, with up to 18 months' follow‐up. Results We analysed two matched groups of 107 participants each, who comprised on average 63.6% men, aged 64 years, with diabetes duration of approximately 10 years, body mass index of 29 kg/m2 and HbA1c level of 7.7–7.8% (61‐62 mmol/mol). The proportion of low, intermediate and high doses were similar with the oral and the injectable formulation. The change in HbA1c was similar between groups (−0.9% / ‐10 mmol/mol at 18 months) as was the proportion of individuals reaching HbA1c <6.5% (48 mmol/mol). The average change in body weight was similar in the two groups (−3.7 kg with injectable and −3.3 kg with oral at 18 months) but more new users of injectable semaglutide lost ≥5% body weight. Persistence on drug was longer with injectable than with oral semaglutide. Conclusion In a real‐world setting, improvements in HbA1c and body weight were similar after initiation of oral or injectable semaglutide. These results may be specific to the features of the matched cohorts under investigation, with limited generalizability to populations with different characteristics.

endocrinology & metabolism
A survey of the American species of vaccinium, subgenus euvaccinium

W. H. Camp

DOI: https://doi.org/10.2307/2804714

1942-04-01

Brittonia

Abstract:In the preceding paper I have noted the possibility that fu ture work on the phylogeny of the Vaccinieae may indicate the need for generic realignments within the tribe, eventually influencing the circumscription of the genus Vaccinium. However, no nomenclatural changes would be necessary in the group here under consideration for it contains the nomenclatural type of the genus. Nevertheless, it should be stated that, in my opinion, this group-toge ther with other forms which are outside the present discussion--merits at least the rank of subgenus. I t is to be noted that, as originally set up by Asa Gray, this subgeneric group contained V. uliginosum and V. occidentale. These have been excluded on the basis of their different type of inflorescence. The proper citation for this group, which contains the American bilberries, is: Vaccinium subgenus Euvaccinium (A. Gray) Klotzsch, Linnaea 24: 54, 58. 1851 (pro par te) . The type species is Vaccinium myrtillus L. Since nomenclature will play a minor role in the present discussion, it will scarcely be necessary to go into greater detail concerning these matters in this place. In the foregoing paper some consideration was given to the dynamics of speciation within the eastern American members of the genus Vaccinium, subgenus Cyanococcus. There it was noted that the evidence indicates that this g roupthe t rue blueberries--is not genetically unusual within the family. I t is therefore held as axiomatic that the American bi lberr ies-in the subgenus Euvaccinium, and from the standpoint of their basic cytogenetic phenomena--are probably neither unique nor different from the i r relatives. Fur thermore, the distribution patterns and morphological variations which one finds among the species of American bilberries are so similar to those in other segments of the genus which have been studied that one is direct ly led to the conclusion that the same forces have been operative in their production. Therefore, in my conclusions I have had little hesitation in going somewhat beyond the available data. This may be scientifically unsound; nevertheless, it is the best I can do unti l the actual data are available. At least, this procedure has brought to the present discussion a point of view without which we should have no explanation of the possible reasons for the different types of variabilities which are so obvious when the material is studied.
Long anterior urethral reconstruction using a jejunal free flap

S. Tourbach,D. Hunter-Smith,W. Morrison

DOI: https://doi.org/10.3109/02844311.2010.504073

2011-02-01

Journal of Plastic Surgery and Hand Surgery

Abstract:Abstract We report the case of a transgender patient who was referred to our department for management of chronic strictures of his neophalloplasty. We successfully used a free jejunal flap for a long anterior urethral reconstruction. He achieved a patent and functional urethra with satisfactory urinary control and was happy with the cosmetic outcome.
PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes

Ponnusamy Saravanan,Heather Bell,Uffe Christian Braae,Edward Collins,Alisa Deinega,Ketan Dhatariya,Alena Machell,Antonia Trent,Anna Strzelecka

DOI: https://doi.org/10.1007/s12325-024-02973-z

Abstract:Introduction: Oral semaglutide provides an alternative to injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs) for treatment of type 2 diabetes (T2D). The PIONEER REAL studies evaluate clinical outcomes of oral semaglutide treatment of T2D in a real-world setting. PIONEER REAL UK focused on adults living with T2D in the UK. Methods: The multi-centre, prospective and non-interventional single-arm study enrolled 333 participants and followed them for 34-44 weeks. Participants were treated as part of routine clinical practice and had not been previously treated with injectable glucose-lowering medication. The primary endpoint was change in glycated haemoglobin (HbA1C) from baseline to end of study (EOS). Secondary endpoints included change in body weight, proportion of participants with HbA1C < 7% (53 mmol/mol) at EOS and proportion of participants with ≥ 1%-point HbA1C reduction and body weight reduction of ≥ 3% or ≥ 5% at EOS. Treatment satisfaction was assessed by Diabetes Treatment Satisfaction Questionnaire (DTSQ) status and change. Results: Of 333 participants, 299 completed the study and 227 were on treatment at EOS. People treated with oral semaglutide experienced significantly reduced HbA1C by an estimated change of - 1.1%-points (95% CI - 1.27 to - 0.96; P < 0.0001) or - 12.2 mmol/mol (CI - 13.87 to - 10.47; P < 0.0001). Estimated change in body weight was - 4.8 kg (CI - 5.47 to - 4.12; P < 0.0001). At EOS, an HbA1C level < 7% (53 mmol/mol) was recorded in 46.3% of participants. A ≥ 1%-point reduction in HbA1C combined with a ≥ 3% reduction in body weight was observed in 36.4% of participants, and 27.1% had a ≥ 1%-point reduction in HbA1C and a ≥ 5% body weight reduction. Treatment satisfaction improved significantly during the study. No new safety concerns or cases of severe hypoglycaemia were reported. Conclusion: People living with T2D in the UK experienced a meaningful decrease in HbA1C and body weight after initiation of oral semaglutide treatment. No new safety issues were observed. Trial registration: ClinicalTrials.gov: NCT04862923. Graphical plain language summary available for this article.

Posterior segment injury developed after injection of anesthetics on eyelids with needleless jet injection device

Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting

Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings

A meta-analysis of thoracic radiotherapy for small-cell lung cancer.

In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis.

Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data

Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial

Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice

Ultrafast laser ablation giving unstructured surface roughness prior to the emergence of LIPSS

Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study)

PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice

Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study

PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan

Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study)

Once‐weekly semaglutide use in patients with type 2 diabetes: real‐world data from the SURE Italy observational study

Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics

Doppler tissue imaging in the assessment of atrioventricular conduction time: validation of a novel technique and comparison with electrophysiologic and pulsed wave Doppler-derived equivalents in an animal model.

Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts

A survey of the American species of vaccinium, subgenus euvaccinium

Long anterior urethral reconstruction using a jejunal free flap

PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes